Millions of UK seniors prescribed dementia-linked anticholinergics without risk warnings

A recent analysis reveals that more than four million UK residents aged 65 and over are on at least one anticholinergic medication, a class linked to an increased chance of developing dementia, yet standard patient leaflets omit any reference to this risk. Prescription volumes have more than doubled since 2005, climbing from 2.6 million to 6.2 million annually. Geriatrician Lucy Pollock stresses the need for transparent communication, noting that prescribing systems rarely flag these drugs.

Research from the University of Nottingham found an 18 % higher dementia incidence among users of bladder anticholinergics such as oxybutynin, while non-anticholinergic alternatives like mirabegron showed no significant risk. Tony Avery, now NHS England’s national clinical director for prescribing, previously called for immediate action to curb use for bladder symptoms. Although the MHRA acknowledges the heightened side-effect profile of combined anticholinergics, it stopped short of requiring label changes, urging patients to discuss concerns with clinicians. The issue sits within a broader over-prescribing crisis, with millions of older adults taking multiple drugs that amplify adverse effects.